Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
NCT ID: NCT00523614
Last Updated: 2010-03-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3400 participants
OBSERVATIONAL
2007-07-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bleeding Pattern Study
NCT00302666
Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition
NCT00471991
Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest
NCT01600274
Construction and External Validation of a Predictive Clinico-biological Score of the Risk of Venous Thrombosis in Women Under Combined Oral Contraceptives
NCT03309293
Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding
NCT01638923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cases are women who are between 15 and 49 years old with a diagnosis of venous thromboembolism (VTE). The VTE is diagnosed in Germany between January 2002 und December 2007.
Controls are women who are between 15 and 49 years old without a VTE diagnosis. About 4 controls matched by year of birth and region will be allocated to each case.
Both cases and controls will receive a similar self-administered questionnaire except of some case-specific questions which are not applicable for the controls.
Study participants will be asked for their informed consent. Data confidentiality will be ensured by the Berlin Center for Epidemiology and Health Research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: Cases
No interventions assigned to this group
2: Controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* control: women without a venous thromboembolism diagnosis who are between 15 and 49 years old
Exclusion Criteria
* women with severe language problems
* women who are not willing to participate
15 Years
49 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Center for Epidemiology and Health Research, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Center for Epidemiology and Health Research, Germany
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juergen C Dinger, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Center for Epidemiology and Health Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Epidemilogy and Health Research
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZEG2007_02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.